Tag - ALT

Markets

Roth resumes coverage of Altimmune at buy; PT $13

Roth Capital Partners resumed coverage of Altimmune (NASDSQ:ALT) with a “buy” rating and $13 price target. The stock closed at $1.76 on Feb. 21. “Altimmune represents a buying opportunity with its dual GLP-1: glucagon...

February 24, 2020

Developments

Altimmune’s NasoVAX provides 100% seroprotection more than one year after vaccination

Altimmune’s (NASDAQ:ALT) intranasal influenza vaccine, NasoVAX, demonstrated a seroprotective antibody response in all subjects who received the vaccine more than one year ago. The Phase 2a trial of NasoVAX was...

March 20, 2019

Tag - ALT

Roth resumes coverage of Altimmune at buy; PT $13

Altimmune’s NasoVAX provides 100% seroprotection more than one year after vaccination

General

More